Murat CAGLAYAN

Murat CAGLAYAN


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ETEbru TEMİZ
Ebru TEMİZ
IKIsmail Koyuncu
Ismail Koyuncu
MDMustafa DURGUN
Mustafa DURGUN
MCMurat CAGLAYAN
Murat CAGLAYAN
AGAtaman Gönel
Ataman Gönel
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
Carbonic anhydrase IX (CAIX) is a hypoxia-related protein that plays a role in proliferation in solid tumours. However, how CAIX increases proliferation and metastasis in solid tumours is unclear. The objective of this study was to investigate how a synthetic CAIX inhibitor triggers apoptosis in the HeLa cell line. The intracellular effects of CAIX inhibition were determined with AO/EB, AnnexinV-PI, and γ-H2AX staining; measurements of intracellular pH (pHi), reactive oxygen species (ROS), and mitochondrial membrane potential (MMP); and analyses of cell cycle, apoptotic, and autophagic modulator gene expression (Bax, Bcl-2, caspase-3, caspase-8, caspase-9, caspase-12, Beclin, and LC3), caspase protein level (pro-caspase 3 and cleaved caspase-3, -8, -9), cleaved PARP activation, and CAIX protein level. Sulphonamide CAIX inhibitor E showed the lowest IC50 and the highest selectivity index in CAIX-positive HeLa cells. CAIX inhibition changed the morphology of HeLa cells and increased the ratio of apoptotic cells, dramatically disturbing the homeostasis of intracellular pHi, MMP and ROS levels. All these phenomena consequent to CA IX inhibition triggered apoptosis and autophagy in HeLa cells. Taken together, these results further endorse the previous findings that CAIX inhibitors represent an important therapeutic strategy, which is worth pursuing in different cancer types, considering that presently only one sulphonamide inhibitor, SLC-0111, has arrived in Phase Ib/II clinical trials as an antitumour/antimetastatic drug.

19 April 2021 in Clinical Endocrinology
Verified
Journal Article
Open access
PDF file
MSMustafa - Sahin
Mustafa - Sahin
CHCem Haymana
Cem Haymana
IDIbrahim Demirci
Ibrahim Demirci
ITIlker Tasci
Ilker Tasci
RERıfat Emral
Rıfat Emral
Alper SonmezAlper Sonmez
Alper Sonmez
Background: There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID‐19) disease outcomes and mortality. Here, we evaluated COVID‐19 infection outcomes and mortality in thyroid cancer patients with COVID‐19 infection.Design and methods: We included a cohort of patients with thyroid cancer with PCR‐confirmed COVID‐19 disease from 11 March to 30 May 2020 from the Turkish Ministry of Health database in our nationwide, retrospective study. We compared the mortality and morbidity of COVID patients with or without thyroid cancer. Univariate and multivariate analyses were used to assess the independent factors for mortality, length of hospital stay and intensive care unit (ICU) admission and mechanical ventilation. We also analysed the effect of radioiodine treatment on severity and death rate of COVID‐19 disease.Results: We evaluated 388 COVID‐19 patients with thyroid cancer [median age: 54 years, interquartile range (IQR) 18 years, males: 23%] and age and gender‐matched 388 COVID‐19 patients without thyroid cancer. Patients with thyroid cancer had a similar mortality ratio compared with the non‐cancer group. Among patients with thyroid cancer, age, presence of diabetes mellitus, asthma/COPD, heart failure, chronic kidney disease, prior coronary artery disease, RAS blocker usage and low lymphocyte count were associated with mortality. Radioactive iodine (RAI) treatment and cumulative radioactive iodine dosage did not negatively affect the severity and mortality of COVID‐19 disease in our patient group.Conclusions: Our study indicated that history of thyroid cancer did not have an increased risk of mortality or morbidity in COVID‐19 disease. Besides, RAI therapy history and doses of radioactive iodine did not affect mortality or outcome.

7 September 2022 in Gulhane Medical Journal
Verified
Journal Article
Closed access
ZAZülfikar Akelma
Zülfikar Akelma
MKMelikşah Keskin
Melikşah Keskin
ŞEŞenay Savaş Erdeve
Şenay Savaş Erdeve
NBNurbanu Bursa
Nurbanu Bursa
OÇOsman Çelik
Osman Çelik
SBSUAYIP BIRINCI
SUAYIP BIRINCI

15 October 2022 in Journal of Medical Biochemistry
Verified
Journal Article
Open access
PDF file
MCMurat CAGLAYAN
Murat CAGLAYAN
CSCigdem Sonmez
Cigdem Sonmez
MSMehmet Senes
Mehmet Senes
AGAtaman Gonel
Ataman Gonel
OGOzlem Gulbahar
Ozlem Gulbahar
SBSuayip Birinci
Suayip Birinci
Background: Across the world, 25-hydroxyvitamin D (25-OHD) deficiency is a major health problem associated with many chronic diseases in the geriatric population. Prior to this study, there were no data regarding 25-OHD levels among individuals over the age of 65 in Turkey. The aim of this study was to assess 25-OHD levels and seasonal variations in these values among people over the age of 65 in Turkey. Methods: This study included vitamin D measurements taken in 2016, 2017, and 2018 from the Turkish population over the age of 65. The age, gender, and seasonal average data of the study population were defined. The study data were obtained from the database of the Ministry of Health, and a Kolmogorov-Smirnov test was used to assess the distribution of the data. Medians and interquartile ranges (IQRs) were calculated for all categories, as the data were nonparametric. Results: The number of vitamin D measurements taken from the geriatric individuals included in this study was 305,329 for 2016, 576,452 for 2017, and 752,837 for 2018. The medians and IQRs of the 25-OHD levels in this population were 16 mg/L (IQR 7.45-24.55 mg/L) for 2016, 16.1 mg/L (IQR 7.8-24.4 mg/L) for 2017, and 16.4 mg/L (IQR 8.95-23.85 mg/L) for 2018. Conclusions: While the 25-OHD levels of older men tended to increase during the period of seasonal sunlight in Turkey, this variability was observed in elderly women. This suggests that older women tend to live more sedentary lives and have insufficient sun exposure. Overall, the median 25-OHD levels of individuals over the age of 65 tended to decrease each year.

18 October 2024 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
HSHasan Satiş
Hasan Satiş
AEAbdulsamet Erden
Abdulsamet Erden
EBEmre Bilgin
Emre Bilgin
GAGi̇zEm Ayan
Gi̇zEm Ayan
BABerkan Armağan
Berkan Armağan
ŞBŞuayi̇p Bi̇rİnCi̇
Şuayi̇p Bi̇rİnCi̇
Aim: Rheumatoid factor (RF) and Anti Citrullinated Peptide (anti-CCP) is specific for rheumatoid arthritis (RA) diagnosis. However they could be positive in other disease and even healthy populations. It was aimed to investigate the prevalence of positive RF and anti-CCP antibodies in persons admitted to hospital for any reason and on a national scale.Material and Method: The National Electronic Health Database, which contains the clinical records of over eighty million people, is used to design this multi-center, retrospective cohort study. The subjects included in the study were divided into age groups in 10-year periods. RA cases were identified by using ICD-10 codes that included M05,M06, M08,and their subgroups. RF and anti-CCP positivity were evaluated in terms of their contribution to the risk of being diagnosed with RA, with the change according to age and genderResults: During the 1.1.2018-31.12.2021 period, 13.918.072 RF tests were performed in 11.849.440 people, whereas 1.183.607 anti-CCP test were performed in 1.020.967 people. 797.089 people had at least once both tests performed. RF positivity rate in patients who only requested RF test was 14.72% and it was 35.04% for anti-CCP positivity in only requested anti-CCP tests. The rate of concomitant RF and anti-CCP positivity was 22.56%.RA diagnosis is made in in 27.8% of RF-positive people, in 39.73% of anti-CCP-positive people and in %56.6 of co RF and anti CCP positive people. RF positivity and concomitant RF and anti-CCP positivity increased with the age and more common in females.Conclusion: RF and anti-CCP positivity could be seen in a healthy population with female predominance. As the age increases, the risk of RF positivity is increased, however anti –CCP positivity does not change. Concomitant RF and anti-CCP positivity has the highest risk of RA development with respect to either antibody positivity alone.

1 September 2021 in Public Health
Verified
Journal Article
Closed access
BDBedia Dinç
Bedia Dinç
FKF. Kirca
F. Kirca
SAS. Aydogan
S. Aydogan
ATA. Toyran
A. Toyran
TBT. Basyigit
T. Basyigit
ASA.A. Surel
A.A. Surel